Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Doc - whether or not Mr Costas attends the agm - who cares? Those who can will, and those who can’t won’t. The issue is, why can’t he be allowed to complain about a business that has sustained such a significant depreciation in value? He raises perfectly legitimate questions in my view, and the relentless assault on his every post is baffling to me. A balanced discussion and tolerance for the views of others - surely that’s how we form if need be adjust our opinions isn’t it?
Sorry but I struggle to understand why some contributors to this chat forum react in such an offensive way to MrCosts posts. This business is nigh on 20 years old. No product in the marketplace, and not remotely close to having a licensed product. Synairgen is still entirely dependant on investors paying for operational costs and very substantial salaries. Last cash raise at 175p. Share price now around 8p. So, do investors not have a right to grumble,complain,criticise? Of course we do.This business is under forming on an epic scale. So why throw barbs at those who speak the self evident?
Spot on Spacman. The fat cats are heads down in the trough whilst their investors burn. Two decades on and no product in the marketplace or even remotelessly close. Still totally reliant on Institutional and private investors funding their very substantial salaries and operating costs. Still, “we know it works”, and they are of course “working at haste”.
Who takes responsibility for the phase 3 fiasco? Will those responsible for designing the trial be involved in any future trial design? We don’t know is the answer.
We all invested because we believed in the science. The science is never enough. This business is stale. We need new leadership with fresh energy, focus, and commercial nous. RM has taken enough of my hard earned
Sharedealer _ with respect, nigh on 20 years is long haul enough for some of us. Still no marketable product, still loss making and a relentlessly depreciating sp. the business is stale and we need a new dynamic CEO. we also need top drawer business savvy communicators
Post Sprinter failure there should have been a clear out. New dynamic CEO and freshen up the board with commercial expertise. Nigh on 20 years is enough. The folk running this business are incapable of getting this single product over the line
In a world of finite resources RM could have saved a lot of ink by simply saying, “Happy New Year to all our investors. I can confirm that 2023 will be business as usual. Oh, and soz about the phase 3 failure. Never mind eh”
And sp now 16.49p. Jeez. Those of us who financed the sprinter trial say anything negative and we are trolls or derampers. No, just disillusioned and angry at the inertia. Does anyone doubt that a major pharma would have taken nearly 20 years toget this product over the line? They tell us “we know it works”. Cmon, bat it over to people who know how to get a drug into the marketplace
17.5p close. Joint venture, buyout, Strive, blah blah blah. Oops soz, forgot, gotta be positive and any doubts about this business and the fat cats coining it in for nearly two decades strictly not allowed. I’ll get my coat